Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine

Nucleosides, Nucleotides and Nucleic Acids

Volumn 27, Issue 6-7, 2008, Pages 779-786

  Leisewitz, Andrea V ^a   Zimmerman, Eric I ^a   Jones, Shannon Z ^a   Yang, Jing ^a   Graves, Lee M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Equilibrative nucleoside transporter; Gemcitabine; Imatinib

Indexed keywords

BCR ABL PROTEIN; GEMCITABINE; IMATINIB; MESSENGER RNA; NUCLEOSIDE TRANSPORTER; PROTEIN ENT1; PROTEIN ENT2;

ANIMAL CELL; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESISTANCE; LEUKEMIA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATTLE; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; NUCLEOSIDE TRANSPORT PROTEINS; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER; TIME FACTORS;

EID: 46749155824     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770802145892     Document Type: Conference Paper

References (18)

1. .Kantarjian, H.M.; O'Brien, S.; Anderlini, P.; Talpaz, M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996, 87, 3069-3081.
2. Faderl, S.; Talpaz, M.; Estrov, Z.; Kantarjian, H.M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 1999, 131, 207-219.
3. Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2, 561-566.
4. Kantarjian, H.M.; Cortes, J.; O'Brien, S.; Giles, F.J.; Albitar, M.; et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002, 99, 3547-3553.
5. O'Brien, S.; Giles, F.; Talpaz, M.; Cortes, J.; Rios, M.B.; et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003, 98, 888-893.
6. Fruehauf, S.; Topaly, J.; Buss, E.C.; Fischer, T.; Ottmann, O.G.; et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007, 109, 1543-1549.
7. Lech-Maranda, E.; Korycka, A.; Robak, T. Influence of gemcitabine (2′,2′-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. Eur. J. Haematol. 2000, 65, 317-321.
8. Giovannetti, E.; Mey, V.; Loni, L.; Nannizzi, S.; Barsanti, G.; et al. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol. Res. 2007, 55, 343-349.
9. Baldwin, S.A.; Mackey, J.R.; Cass, C.E.; Young, J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today. 1999, 5, 216-224.
10. Clarke, M.L.; Mackey, J.R.; Baldwin, S.A.; Young, J.D.; Cass, C.E. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.Cancer Treat. Res. 2002, 112, 27-47.
11. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol., 2002, 3, 415-424.
12. Huang, M.; Wang, Y.; Cogut, S.B.; Mitchell, B.S.; Graves, L.M. Inhibition of nucleoside transport by protein kinase inhibitors. J. Pharmacol. Exp. Ther. 2003, 304, 753-760.
13. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001, 25, 402-408.
14. Wang, J.; Schaner, M.E.; Thomassen, S.; Su, S.F.; Piquette-Miller, M.; et al. Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharm. Res. 1997,,14, 1524-1532.
15. Gray, J.H.; Owen, R.P.; Giacomini, K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 2004, 447, 728-734.
16. Pastor-Anglada, M.; Felipe, A.; Casado, F.J. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends Pharmacol. Sci. 1998, 19, 424-430.
17. Damaraju, V.L.; Damaraju, S.; Young, J.D.; Baldwin, S.A.; Mackey, J.; et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003, 22, 7524-7536.
18. Garcia-Manteiga, J.; Molina-Arcas, M.; Casado, F.J.; Mazo, A.; Pastor-Anglada, M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity. Clin. Cancer Res., 2003, 9, 5000-5008.